Other FDA-approved angiogenesis blocking agents include inhibitors of receptor tyrosine kinases (RTK) regorafenib (approved for the treatment of refractory mCRC), ramucirumab (for cancers of gastro-intestinal tract, NSCLC, mCRC), sorafenib (for RCC, hepatocellular carcinoma (HCC), thyroid cancer), sunitinib (for RCC, pancreatic neuroendocrine tumours), pazopanib (for RCC, soft tissue sarcoma), axitinib (for RCC), vandetanib (for thyroid cancer), lenvatinib (for thyroid cancer), nintedanib (for NSCLC), and others [213]. This evidence concerns the gene NTRK1 and hepatocellular carcinoma.